Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, VistaPath Biosystems is raising $6,316,444.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Timothy Spong played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About VistaPath Biosystems
VistaPath Biosystems is modernizing pathology labs using machine augmentation. Despite informing a majority of clinical decisions, anatomical pathology still prepares samples for diagnosis manually, in stark contrast to other clinical lab services. Driven by computer vision, we have developed a Workflow Management System which relieves highly paid technicians from manual tissue processing.

To learn more about VistaPath Biosystems, visit http://www.vistapathbio.com/

Contact:
Timothy Spong, Chief Executive Officer
917-301-7571
https://www.linkedin.com/in/timothy-spong-a5529572/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved